Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd has a market capitalization of $184.53 million, with a current market price of $1.45 per share. The company has 127,259,131 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks. Without access to key financial metrics such as net profit margin, return on equity, or return on invested capital, it is not possible to evaluate the company's efficiency or profitability relative to its peers. Tiziana Life Sciences Ltd does not disclose segment or geographic revenue breakdowns in the available data, which limits the ability to assess the concentration of its revenue sources. This lack of transparency could pose a risk to investors who are interested in understanding the geographic and product diversification of the company. The company's growth trajectory is not quantifiable wi
Business. Tiziana Life Sciences Ltd (TLSA.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United Kingdom and primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Tiziana Life Sciences Ltd (TLSA.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United Kingdom and primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Tiziana Life Sciences Ltd has a market capitalization of $184.53 million, with a current market price of $1.45 per share. The company has 127,259,131 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks. Without access to key financial metrics such as net profit margin, return on equity, or return on invested capital, it is not possible to evaluate the company's efficiency or profitability relative to its peers.
Tiziana Life Sciences Ltd does not disclose segment or geographic revenue breakdowns in the available data, which limits the ability to assess the concentration of its revenue sources. This lack of transparency could pose a risk to investors who are interested in understanding the geographic and product diversification of the company.
The company's growth trajectory is not quantifiable with the current data, as there are no historical revenue figures or forward-looking guidance provided. Analysts have assigned a mean price target of $8.00, with a median and high target also at $8.00, suggesting a consensus for significant upside potential. However, the mean recommendation of 2.00 (on a scale from 1 to 5) indicates a "Buy" rating, with only one analyst recommending a "Buy" and none recommending a "Strong Buy".
The risk assessment for Tiziana Life Sciences Ltd highlights a low dilution risk, but the liquidity risk remains unassessed. The absence of balance-sheet inputs and no going-concern language in source documents raises concerns about the company's ability to meet short-term obligations.
There are no recent events or filings mentioned in the available data that would provide insight into the company's operational or strategic developments. The lack of recent disclosures or transcripts limits the ability to assess the company's current status or future plans.
- Tiziana Life Sciences Ltd is a biotechnology company with a market capitalization of $184.53 million.
- Analysts have assigned a mean price target of $8.00, indicating a potential for significant upside.
- The company has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
- The company's profitability and return metrics are not available, making it difficult to assess its performance against industry benchmarks.
- The liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- **margin_outlook_rationale**: Not available due to lack of financial data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income +46,7% YoY; Net income +34,2% YoY.
- ▍Operating income +46,7% YoY
- ▍Net income +34,2% YoY
- ▍Free cash flow +34,1% YoY
Revenue $0.00; Operating income -$27.4M.
- ▍Revenue $0.00
- ▍Operating income -$27.4M
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,20 |
| Revenue | —no estimate | —no estimate | 0 |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Tiziana Life Sciences Ltd Market data — financials · 2026-05-29
- Tiziana Life Sciences Ltd Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Leadership
- Gabriele Marco Antonio CerroneExecutive Chairman of the Board
Insider activity
- Director, 10% owner · COMMON STOCKOther 15 000 @ $1,11$17K · 2026-06-12